RSV-IGIV therapy: a cost/benefit analysis.
Thakur
B K
BK
Wu
L R
LR
Schaeufele
J F
JF
D001997:Bronchopulmonary Dysplasia / Q000150:complications; D003362:Cost-Benefit Analysis; D003422:Critical Care / Q000191:economics; D017722:Hospital Charges; D006760:Hospitalization / Q000191:economics; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D010102:Oxygen Inhalation Therapy / Q000191:economics; D010343:Patient Admission / Q000191:economics; D012121:Respiration, Artificial / Q000191:economics; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous; C098685:respiratory syncytial virus immune globulin intravenous